Multiple-dose pharmacokinetics and safety of two regimens of quinupristin/dalfopristin (synercid™) in healthy volunteers

Journal of Clinical Pharmacology

Volumn 41, Issue 4, 2001, Pages 404-414

  Chevalier, P ^a   Rey, J ^a   Pasquier, O ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN;

ADULT; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GRAM POSITIVE BACTERIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; PLASMA CLEARANCE;

ADOLESCENT; ADULT; AREA UNDER CURVE; BIOLOGICAL ASSAY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG THERAPY, COMBINATION; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; SKIN DISEASES, BACTERIAL; TIME FACTORS; VIRGINIAMYCIN;

EID: 0035066533     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700122010267     Document Type: Article

References (16)

1. In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium
2. Bactericidal and inhibitory activity of quinupristin/dalfopristin against vancomycin- and gentamicin-resistant Enterococcus faecium
3. Synergic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium
4. Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates
5. A review of in-vitro antibacterial activity of quinupristin/dalfopristin against methicillin-susceptible and -resistant Staphylococcus aureus
6. In vitro activity of quinupristin/dalfopristin (RP 59500) against a large collection of infrequently isolated or tested species
7. The in vitro activity of new streptogramins, RP 59500, RP 57669 and RP54476, alone and in combination
8. Comparative in-vitro activity of RP 59500
9. Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies
10. Open, comparative study of the pharmacokinetics and safety of a single dose of quinupristin/dalfopristin (Q/D, RP 59500, Synercid®) in healthy male and female volunteers
11. Pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans
12. Disposition of the radiolabelled streptogramin RP59500 in healthy male volunteers
13. Simultaneous high-performance liquid chromatographic determination of quinupristin, dalfopristin and their main metabolites in human plasma
14. IGPHARM: Interactive graphic package for pharmacokinetic analysis
15. Pharmacodynamics of macrolides, azalides, and streptogramins: Effect on extracellular pathogens
16. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: Focus on antibacterial agents